Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A form of CMT1, caused by mutations in the EGR2 gene (10q21.1), with a variable severity and age of onset (from infancy to adulthood), that usually presents with gait abnormalities, progressive wasting and weakness of distal limb muscles, with possible later involvement of proximal muscles, foot deformity and severe reduction in nerve conduction velocity. Additional features may include scoliosis, cranial nerve deficits such as diplopia, and bilateral vocal cord paresis.
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 9:40 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease type 1D
Features include always present findings: Decreased motor nerve conduction velocity, Distal muscle weakness, Foot dorsiflexor weakness, and Peripheral neuropathy. 7 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 3 | Upper limb muscle weakness, Distal muscle weakness, Foot dorsiflexor weakness |
Brain and nerves | 2 | Steppage gait, Peripheral neuropathy |
Arms and legs | 2 | Upper limb muscle weakness, Foot dorsiflexor weakness |
EGR2 encodes early growth response 2 (476 aa). Sequence-specific DNA-binding transcription factor. Highest expression in Nerve Tibial (62.6 TPM) and Cells EBV-transformed lymphocytes (32.8 TPM).
Charcot-Marie-Tooth disease type 1D is associated with mutations in the EGR2 gene on chromosome 10.
The EGR2 protein participates in EGR2 gene:POU3F1:POU3F2:SOX10, EGR2 at active HOXA2 chromatin, and EGR2 at active HOXB2 chromatin pathways.
EGR2 is classified as a druggable target (Transcription Factor category) with score 26.1.
Genetic testing for EGR2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 4 always present features.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
3 publications have been identified in PubMed for Charcot-Marie-Tooth disease type 1D. Research spans Basic Science / Preclinical (100%).
Feng S (2026). [PMID: 41640696](https://pubmed.ncbi.nlm.nih.gov/41640696/). *Journal of clinical orthopaedics and trauma*. [Basic Science / Preclinical]
Cashman CR (2025). [PMID: 40400204](https://pubmed.ncbi.nlm.nih.gov/40400204/). *Annals of clinical and translational neurology*. [Basic Science / Preclinical]
Martinez Moreno M (2024). [PMID: 39595160](https://pubmed.ncbi.nlm.nih.gov/39595160/). *Biomedicines*. [Basic Science / Preclinical]
AI-curated news mentioning Charcot-Marie-Tooth disease type 1D
Updated Aug 21, 2026
Research demonstrates that tyrosine supplementation can rescue growth defects in a humanized S. cerevisiae model associated with YARS1 mutations linked to Charcot-Marie-Tooth disease type 1D. This study highlights potential therapeutic avenues for addressing growth issues in affected individuals.